Integra LifeSciences(IART) - 2023 Q4 - Earnings Call Presentation

Note: Organic growth; Adj EBITDA and Adj EPS are non-GAAP financial measure. 6 IART Q4 2023 Earnings Presentation Note: Adj. EBITDA margin, and adj. EPS are non-GAAP financial measures. Codman Specialty Surgical Q4 Revenue Adj. EBITDA Margin 25.3% (230bps) vs. 2022 Q4 Revenue and adj. EPS within guidance range Tissue Technologies Q4 Revenue Revenues Q4'23 Q4 Growth Q4 Growth excl. Boston Organic1 $122.7M (8.0%) 6.9% 7.2% | --- | --- | --- | |----------------------|------------------------------------------- ...